Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Committee Closes Books On 2016 Pricing Investigation; PBMs In Hot Seat Next?

Executive Summary

US Senate Aging Committee wrapped up its investigation into price spikes for off-patent drugs with some relatively unsurprising (and – for most innovator companies – unthreatening) policy recommendations; a brief coda to the report offers two possible directions for future investigations: abuse of the patent system – or the impact of PBM practices.

You may also be interested in...



Drug Pricing ‘Biggest Offenders’ Are Annual Increases On Widely Used Brands

Express Scripts Chief Medical Officer Steve Miller suggests that caps on annual price increases could significantly ease payer concerns over drug pricing.

Drug Affordability Review By National Academies Kicks Off With Lower Profile Than Expected

A National Academies of Sciences, Engineering and Medicine project on drug access and affordability is kicking off with a very different political backdrop for its deliberations than the one that seemed likely when the working group was selected in late October; its work may still end up mattering a great deal, if and when innovator pricing is back on the table for serious policy review.

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

GDUFA II gives certain generics the possibility of an even faster review clock, which burnishes FDA's credentials in the drug pricing debate, but in order to take advantage, applications will need to be of high quality in addition to addressing a public health priority.

Related Content

Topics

UsernamePublicRestriction

Register

PS119766

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel